Tag: Diabetes: Type II
Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM
Greater reduction in urinary albumin-to-creatinine ratio seen for combination versus either agent alone
Concurrent Hypertension + Type 2 Diabetes Predict High Mortality Risk
Higher all-cause and cardiovascular mortality predicted with concurrent hypertension and type 2 diabetes
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
Proportion of adult managed care organizations with availability varied from 24 to 100 percent for SGLT2 inhibitors, 0 to 99 percent for GLP-1 receptor agonists
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
Combined use of SGLT2 inhibitors and GLP-1 receptor agonists also significantly increased the risk for falls
GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM
Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them
Certain Combinations of Food Additives May Increase Risk for Type 2 Diabetes
Authors say limiting certain food additives may be an effective public health strategy to prevent diabetes
Tirzepatide Dispensations Increased Rapidly After Approval
By December 2023, 12.3 percent of all glucose-lowering medication dispensations were tirzepatide among adults with T2DM
ACP: Switching From Dulaglutide to Tirzepatide Improves HbA1c Reduction in T2DM
Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide
ACC: Semaglutide Beneficial in Patients With T2DM and Peripheral Artery Disease
Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes
Minimal TV Viewing May Cut ASCVD Risk in Those With T2DM Genetic Risk
Medium and high T2DM genetic risk not linked to increased risk for ASCVD when TV viewing is no more than one hour/day
